Andere Sprachen Heidelberg Pharma AG

Aktien

A11QVV

DE000A11QVV0

HPHA

Markt geschlossen - Xetra Andere Börsenplätze 17:36:28 03.05.2024			% 5 Tage	% 1. Jan.
2,98 ^EUR	0,00 %		-1,65 %	-20,32 %

25.04.	Heidelberg Pharma AG meldet Ergebnis für das erste Quartal bis zum 29. Februar 2024	CI
23.04.	Transcript : Heidelberg Pharma AG - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Heidelberg Pharma : Remuneration Report 2023	29.04.
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024	25.04.
Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024	25.04.
DD: Heidelberg Pharma AG: Walter Miller, buy	17.04.
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR	05.04.
PM: Heidelberg Pharma receives Orphan Drug Designation from the FDA for its ATAC candidate HDP-101	28.03.
Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment	27.03.
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101	27.03.
DD: Heidelberg Pharma AG: Dr. Georg F. Baur, buy	26.03.
Heidelberg Pharma : Presentation Analyst and Press Conference 2024	25.03.
Heidelberg Pharma : Präsentation Bilanzpressekonferenz 2024	25.03.
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023	25.03.
Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2023	25.03.
Heidelberg Pharma : Presentation	21.03.
Heidelberg Pharma Concludes Royalty Purchase Deal with HealthCare Royalty	19.03.
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty	19.03.
Heidelberg Pharma : Statement on Corporate Governance 2023 as of 19 March 2024	19.03.
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study	18.03.
PM, Heidelberg Pharma Presents Initial Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR 2024 Meeting	07.03.
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024	06.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Heidelberg Pharma AG

Aktien

A11QVV

DE000A11QVV0

HPHA

Andere Sprachen

Filter